Imdelltra plus Imfinzi improves survival in first-line maintenance extensive-stage small-cell lung cancer

This is a new, forward-looking clinical-study result rather than market-performance commentary. Reuters reports that full results from the 563-patient Phase 3 DeLLphi-305 study presented on October 24, 2026 showed a 58% reduction in the risk of death and median overall survival of 21.1 months with Imdelltra plus Imfinzi versus 12.7 months with Imfinzi alone in first-line maintenance extensive-stage small-cell lung cancer. Amgen and AstraZeneca had previously disclosed that the study met its overall-survival endpoint, but the detailed numerical results were newly reported at the medical meeting; therefore, the incremental surprise is meaningful but not extreme. The result could support future label expansion and commercial growth for both sponsors, although the combination was not yet approved for this setting. The exact presentation time is not stated, so the occurrence timestamp is normalized to the start of the reported date in UTC. Only the direct sponsors and Roche, a competitor in the same extensive-stage small-cell lung cancer market, are approved as stakeholders; indirect manufacturing, distribution, and later-line exposure are too speculative.